Overview

DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy

Status:
Not yet recruiting

Trial end date:
2030-01-01

Target enrollment:

Participant gender:

Summary

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of DAY101 monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Day One Biopharmaceuticals, Inc.

Collaborator:

SIOPe Brain Tumor Group LOGGIC Consortium

Treatments:

Antineoplastic Agents